Jason Sheltzer

Sheltzer received a BA in molecular biology from Princeton University and a PhD in biology from the Massachusetts Institute of Technology.[2][3] At MIT, Sheltzer performed his PhD research with Angelika Amon on the consequences of aneuploidy.[4] Sheltzer then established his own research group as an independent fellow at Cold Spring Harbor Laboratory.[5][3] In 2021 Sheltzer was recruited to move his lab to Yale University.[1]

Sheltzer uses CRISPR/Cas9 technology to study aneuploidy and cancer genomics.[6][7] Through the use of chromosome engineering, he has constructed cancer cells with different degrees of aneuploidy, and he has found how aneuploidy affects tumor development and metastasis.[8][9][10] In 2019, he discovered a set of copy number alteration biomarkers that can be used to predict cancer patient outcomes.[5][11][12] His research has questioned whether anti-cancer drugs could be acting through alternate mechanisms.[13][14][15] He is a co-founder of Meliora Therapeutics.[16]

Sheltzer also studies gender disparities in biology research. He discovered that some faculty members, like Nobel Prize winners, tended to hire very few female students in their labs, which could contribute to the gender gap in STEM.[17][18][19]

• Forbes Magazine, 30 under 30 in Science[20]
• American Society for Cell Biology, Gilula Prize[21]
• White House Office of Science and Technology, Presidential Early-Career Science and Engineering Award[22]